MIT Alumni Taris Biomedical Nabs $15M VC Investment to Develop Drug-Delivery Tech | GenomeWeb

Massachusetts Institute of Technology spinout Taris Biomedical said last week that it has raised $15 million in a Series A financing round.

Flagship Ventures, Flybridge Capital Partners, and Polaris Venture Partners co-led the investment.

Taris is a specialty pharmaceutical company that received its initial boost from MIT's Deshpande Center for Technological Innovation to develop drug-device combination therapies invented at the school.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: certain genes repressed during memory formation, analysis of genomes from single neurons, and more.

NASA plans to test whether DNA sequencing studies can be conducted in microgravity.

Congress passes a continuing resolution to keep the US federal government funded through mid-December.

The Human Genome Project was launched 25 years ago, and at Nature, Francis Collins, James Watson, and Eric Green look back at the lessons learned.